UPDATE: MLV Reiterates Buy on Novavax, Reduces PT to $9.50


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


MLV reiterated its Buy rating on Novavax (NASDAQ: NVAX). At the same time, the rating agency reduced its price target on the company's stock from $11 to $9.50. On Thursday, NVAX closed the day at $1.33.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Price TargetReiterationAnalyst RatingsBiotechnologyHealth CareMLV